Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$614M |
| 2 |
Apple
AAPL
|
+$443M |
| 3 |
BLD
TopBuild
BLD
|
+$391M |
| 4 |
SPCX
SpaceX
SPCX
|
+$329M |
| 5 |
Penumbra
PEN
|
+$203M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$1.96B |
| 2 |
NVIDIA
NVDA
|
+$425M |
| 3 |
SNDK
Sandisk
SNDK
|
+$88M |
| 4 |
Southern Company
SO
|
+$80.6M |
| 5 |
PPL
PPL Corp
PPL
|
+$74.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.4% |
| 2 | Industrials | 13.64% |
| 3 | Consumer Discretionary | 9.5% |
| 4 | Healthcare | 7.9% |
| 5 | Financials | 5.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1476
Rocket Pharmaceuticals
RCKT
$385M
| $63.7K | ﹤0.01% |
18,635
-76,545
| -80% | -$255K |
|
1477
Apyx Medical
APYX
$131M
| $63.2K | ﹤0.01% |
+14,069
| New | +$55.8K |
|
1478
Playboy Inc
PLBY
$146M
| $62K | ﹤0.01% |
+50,789
| New | +$77K |
|
1479
Smart Sand
SND
$206M
| $58.8K | ﹤0.01% |
+11,727
| New | +$58.9K |
|
|
OACCW
1480
Oaktree Acquisition Corp III Life Sciences Warrant
OACCW
| $56.5K | ﹤0.01% |
60,000
| – | – |
|
|
SUMAR
1481
SUMA Acquisition Corp Rights
SUMAR
| $56K | ﹤0.01% |
+200,000
| New | +$48K |
|
1482
TechTarget
TTGT
$276M
| $55.1K | ﹤0.01% |
+15,311
| New | +$70.2K |
|
1483
DHI Group
DHX
$182M
| $52.9K | ﹤0.01% |
+14,255
| New | +$47.1K |
|
1484
Palisade Bio
PALI
$366M
| $51.3K | ﹤0.01% |
24,561
+11,436
| +87% | +$22.5K |
|
1485
N-able
NABL
$686M
| $49.8K | ﹤0.01% |
13,573
-265,528
| -95% | -$1.1M |
|
1486
Solid Power
SLDP
$541M
| $48.2K | ﹤0.01% |
+18,611
| New | +$57.5K |
|
|
ELME
1487
Elme Communities
ELME
$148M
| $47.7K | ﹤0.01% |
+32,202
| New | +$65.3K |
|
1488
Apogee Therapeutics
APGE
$10.2B
| $46.2K | ﹤0.01% |
+348
| New | +$31.4K |
|
1489
Pacific Biosciences
PACB
$420M
| $28.6K | ﹤0.01% |
+17,004
| New | +$24.7K |
|
1490
Global X MSCI Vietnam ETF
VNAM
$35.4M
| $24.3K | ﹤0.01% |
+966
| New | +$24.4K |
|
|
PTORW
1491
Praetorian Acquisition Corp Warrant
PTORW
$4.16M
| $24.1K | ﹤0.01% |
63,333
| – | – |
|
1492
Standard BioTools
LAB
$263M
| $22.1K | ﹤0.01% |
+26,867
| New | +$25.4K |
|
1493
EVgo
EVGO
$214M
| $20K | ﹤0.01% |
10,460
+97
| +0.9% | +$195 |
|
|
LEGO.WS
1494
Legato Merger Corp IV Warrants
LEGO.WS
| $13.9K | ﹤0.01% |
33,333
| – | – |
|
|
GPACW
1495
General Purpose Acquisition Corp Warrant
GPACW
| $13K | ﹤0.01% |
50,000
| – | – |
|
1496
SelectQuote
SLQT
$146M
| $12.4K | ﹤0.01% |
+14,770
| New | +$13.4K |
|
1497
Microvision
MVIS
$50.8M
| $12.1K | ﹤0.01% |
+2,460
| New | +$20.3K |
|
1498
SKYX Platforms
SKYX
$156M
| $11.7K | ﹤0.01% |
+10,553
| New | +$11.7K |
|
|
IACOW
1499
Idea Acquisition Corp Warrants
IACOW
$3.21M
| $11.3K | ﹤0.01% |
+33,333
| New | +$11.7K |
|
1500
SkinHealth Systems
SKIN
$85M
| $10.7K | ﹤0.01% |
+15,471
| New | +$11.8K |
|
Similar funds
Michael Gelband's Q2 2026 Portfolio in Review
As of Q2 2026, Michael Gelband held 2,230 positions worth $15.5B, up 23% from $12.6B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Michael Gelband deployed $1.45B of net new capital in Q2 2026, opening 735 new positions and adding to 384 existing holdings. Its largest new stake was SpaceX: 1,938,935 shares worth $331M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 14% a quarter earlier, followed by Industrials and Consumer Discretionary.
On the sell side, the largest reduction was Tesla, an estimated $1.96B trimmed.
- Michael Gelband's largest Q2 2026 buy was SpaceX: 1,938,935 shares worth $331M.
- Michael Gelband added most to Amazon in Q2 2026, an estimated $614M increase.
- Michael Gelband's biggest Q2 2026 reduction was Tesla, cutting an estimated $1.96B.
- Michael Gelband fully exited Southern Company in Q2 2026, selling an estimated $80.6M.
- Michael Gelband's ten largest holdings make up 31% of its $15.5B portfolio in Q2 2026.
- Michael Gelband opened 735 new positions and closed 720 in Q2 2026.
- Michael Gelband's portfolio value rose 23% quarter-over-quarter to $15.5B.
Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.